Galway NUIG spin-out developing off-the-shelf natural killer (NK) cell cancer therapies.
| Date | Round | Amount |
|---|---|---|
| Jan 2022 | Series A Galway cancer-research company ONK Therapeutics raised a $21.5m Series A led by Acorn Bioventures for its NK-cell therapy platform. | $21.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.